Integrated BioPharma Reports Increased Revenue and Net Income Amid Operational Challenges

Company Overview: Integrated BioPharma, Inc. (OTCBB: INBP) is primarily focused on the manufacturing, marketing, and sales of vitamins, nutritional supplements, and herbal products. Its customer base is predominantly located in the United States and Luxembourg.

Recent Financial Performance:

• Sales Revenue (Q3 2025): $13,947,000, up 6.1% from $13,147,000 in Q3 2024.
• Net Income: $611,000 in Q3 2025, compared to $285,000 in the prior year.
• Cost of Sales: Increased to $12,396,000, with gross profit at $1,551,000.
• Operating Income: $739,000, significantly up from $355,000 in Q3 2024.
• Basic Earnings Per Share: Increased to $0.02 from $0.01 year-over-year.

Income Statement Highlights (Nine Months Ended March 31, 2025):

• Total Revenue: $40,178,000, vs. $37,571,000 in the prior year, reflecting a 7% rise.
• Operating Income: Improved to $1,431,000 from a loss of $151,000.
• Net Income: Achieved $986,000, a turnaround from a loss of $156,000.
• Cost of Sales: Inched up by 3.2% to $36,085,000, but as a percentage of sales dropped to 89.8% from 93.1%.

Balance Sheet Insights:

• Total Assets: $25,656,000, down from $26,207,000 as of June 30, 2024.
• Total Liabilities: Reduced to $5,273,000 from $6,969,000.
• Stockholders' Equity: Increased slightly to $20,383,000 from $19,238,000, indicating improved financial leverage.

Challenges and Risks:

• Significant reliance on two major customers for approximately 85% of Q3 sales revenue poses a risk; losing these clients could severely affect revenues.
• The company is facing increased operational costs largely due to inflation, requiring timely price adjustments which may not always be feasible.
• Approximately 78% of employees are under union contracts, which can result in operational challenges if labor negotiations arise.

Outlook:

Integrated BioPharma aims to enhance operational efficiency and diversify its customer base to reduce dependency on major clients. Despite facing inflationary pressures, the company is optimistic about achieving its objectives through strategic management and improved cost controls.